Patients were more likely to have higher five-year and overall survival rates if their state had expanded Medicaid, ...

A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor ...

Niraparib is a “maintenance” drug approved to keep certain types of cancer from coming back, including ovarian cancer, ...

There is widespread misinformation when it comes to prostate cancer. Oncologist Dr Sudipto De debunks 4 myths and stresses the importance of regular screenings.

Recurrent prostate cancer patients with luminal B tumors may benefit from hormone therapy added to radiation following surgery.

Carle Health is offering free cancer screenings in the coming months to help people detect the disease early, which can ...

While outcomes are improving, the report also found cancer incidence rates for younger people aged 30 to 49 are increasing.

Cancer survival rates have improved over three decades as cancer mortality rates decline, according to new data published ...

Researchers found that late-stage, or distant-stage, prostate cancer is increasing across all age groups, including by approximately 3% annually in men under 55 and by 6% in those 55 and older. The ...

In men with prostate cancer, prophylactic whole pelvic radiotherapy does not improve OS compared to prostate-only dose-escalated radiotherapy.

Prostate cancer is now the most common cancer in Australia, as well as being the most common cancer among men, who are much ...

Prostate Cancer Foundation of Australia (PCFA) and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group ...